8-methyl-6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione | 500028-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 8-methyl-6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione
• 英文别名: 8-methyl-6-nitro-2,4-dihydro-1H-3,1-benzoxazine-2,4-dione；8-methyl-6-nitro-1H-3,1-benzoxazine-2,4-dione
• CAS: 500028-91-1
• 化学式: C₉H₆N₂O₅
• 分子量: 222.157
• InChiKey: VLCKMQYUDYOWMA-UHFFFAOYSA-N

物化性质

• 密度：
  1.537±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-methyl-6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione 在 aq NaOH 、 ammonium chloride 、 sodium methylate 作用下， 以 甲醇 、 乙醇 、 水 、 乙腈 为溶剂， 生成 2-溴-3-甲基-5-硝基苯甲酸
  参考文献：
  名称：

  Conjugated complement cascade inhibitors

  摘要：

  本发明涉及共轭的补体级联抑制剂，以及使用共轭的补体级联抑制剂治疗患者的方法。

  公开号：

  US20050004031A1
• 作为产物：
  描述：

  3-甲基衣托酸酐 在 硫酸 、 硝酸 作用下， 以95 %的产率得到8-methyl-6-nitro-1H-benzo[d][1,3]oxazine-2,4-dione
  参考文献：
  名称：

  一种溴氰虫酰胺杂质的合成方法

  摘要：

  本发明公开了一种溴氰虫酰胺杂质的合成方法，该杂质的化学名称为3‑溴‑1‑(3‑氯‑2‑吡啶基)‑N‑[4‑(甲酰胺基)‑2‑甲基‑6‑[(甲氨基)羰基]苯基]‑1氢‑吡唑‑5‑甲酰胺，以2‑氨基‑3‑甲基苯甲酸为起始原料，依次经与三光气环化、硝化、胺酯交换开环、氢化还原、两步酰胺缩合反应，最终得到目标化合物3‑溴‑1‑(3‑氯‑2‑吡啶基)‑N‑[4‑(甲酰胺基)‑2‑甲基‑6‑[(甲氨基)羰基]苯基]‑1氢‑吡唑‑5‑甲酰胺，整套反应路线条件简单，反应过程易操作，经济实用性强。

  公开号：

  CN116496248A

文献信息

• [EN] PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBONYLCHLORIDE COMPOUNDS<br/>[FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉS 1H-PYRAZOLE-5-CARBONYLCHORURES N-SUBSTITUÉS
  申请人：BASF SE

  公开号：WO2013024007A1

  公开（公告）日：2013-02-21

  The present invention relates to a process for preparing an N-substi- tuted 1 H-pyrazole-5-carbonylchloride compound of the formula (I) comprising the steps of i) deprotonating a compound of the formula (II) with a base selected from lithium-organic base having a carbon or nitrogen bound lithium or with a magnesium-organic base having a carbon bound magnesium; and ii) subjecting the product obtained in step (i) to a chlorocarbonylation by reacting it with a reagent selected from the group consisting of phosgene or a phosgene equivalent, to obtain a compound of formula (I).

  本发明涉及一种制备式(I)N-取代1H-吡唑-5-羰基氯化物的过程，包括以下步骤：i) 用选择自碳或氮与锂结合的有机锂碱或碳与镁结合的有机镁碱的碱去质子化式(II)化合物；和ii) 将步骤(i)中获得的产物经氯羰基化反应，与磷酰氯或磷酰氯等效物中选择的试剂反应，以获得式(I)化合物。
• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。
• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• [EN] ANILINE TYPE COMPOUNDS<br/>[FR] COMPOSÉS DE TYPE ANILINES
  申请人：BASF SE

  公开号：WO2013024008A1

  公开（公告）日：2013-02-21

  The present invention relates to compounds of the formula (I) wherein R1 and R2 independently of one another are hydrogen, C1-C10-alkyl, C1-C10-haloalkyl, C3-C10-cycloalkyl, C3-C10-halocycloalkyl, C2-C10-alkenyl, C2-C10-haloalkenyl or together represent an aliphatic chain, or the like; R3 is halogen, cyano, C1-C8-alkyl, C1-C8- haloalkyl, C3-C8-cycloalkyl, C3-C8-halocycloalkyl, C2-C8-alkenyl, C2-C8-haloalkenyl, C1-C8-alkoxy, phenyl, or the like; R4 is hydrogen, C1-C10-alkyl, C1-C10-haloalkyl, C3-C8- cycloalkyl, C3-C8-halocycloalkyl, C2-C10-alkenyl, C2-C10-haloalkenyl, phenyl, or the like; t is 0 or 1; p is 0, 1, 2, 3 or 4. The present invention also relates to a process for preparing a compound of the formula (I) which comprises reacting a compound of the formula (II) with a compound of the formulae (III) or (IV): where t, p, R1 R3, R3 and R4 are as defined in any of claims 1 to 6 and where A- is an equivalent of an anion having a pΚB of at least 10 (determined under standard conditions in water).

  本发明涉及以下式(I)的化合物，其中R1和R2彼此独立地为氢、C1-C10-烷基、C1-C10-卤代烷基、C3-C10-环烷基、C3-C10-卤代环烷基、C2-C10-烯基、C2-C10-卤代烯基或者一起代表一个脂肪链等；R3为卤素、氰基、C1-C8-烷基、C1-C8-卤代烷基、C3-C8-环烷基、C3-C8-卤代环烷基、C2-C8-烯基、C2-C8-卤代烯基、C1-C8-烷氧基、苯基等；R4为氢、C1-C10-烷基、C1-C10-卤代烷基、C3-C8-环烷基、C3-C8-卤代环烷基、C2-C10-烯基、C2-C10-卤代烯基、苯基等；t为0或1；p为0、1、2、3或4。本发明还涉及一种制备上述式(I)化合物的方法，包括将式(II)的化合物与式(III)或(IV)的化合物反应：其中t、p、R1、R3、R3和R4如权利要求1至6中的任一所定义，A-是至少在水中标准条件下具有至少10的pΚB值的阴离子的当量。
• [EN] PROCESS FOR PREPARING N-SUBSTITUTED 1H-PYRAZOLE-5-CARBOXYLATE COMPOUNDS AND DERIVATIVES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ N-1 H-PYRAZOLE SUBSTITUÉ-5-CARBOXYLATE ET DE SES DÉRIVÉS
  申请人：BASF SE

  公开号：WO2013076092A1

  公开（公告）日：2013-05-30

  The present invention relates to a process for preparing an N-substituted 1 H-pyrazole- 5- carboxylate compound of the formula (l-A) comprising the steps of i) deprotonating a compound of the formula (II) in which the variables R1, R2 and r are each as defined in the description and the claims, with a magnesium-organic base having a carbon bound magnesium; and ii) subjecting the product obtained in step (i) to a carbonylation by reacting it with a reagent selected from the group consisting carbon dioxide or a carbon dioxide equivalent, to obtain a compound of formula (l-A); and it relates to further conversions to yield a N-substituted 1H-pyrazole-5-carbonyl chloride compound of the formula (I).

  本发明涉及一种制备式(l-A)的N-取代1 H-吡唑-5-羧酸酯化合物的过程，包括以下步骤：i) 用具有碳键镁的镁有机碱去质子化式(II)的化合物，其中变量R1、R2和r如描述和索赔中定义，并ii) 将步骤(i)中得到的产物经过羰基化反应，与选择自二氧化碳或二氧化碳等效物的试剂反应，得到式(l-A)的化合物；并且涉及进一步的转化以产生式(I)的N-取代1H-吡唑-5-羰基氯化物化合物。